Effect of cyclosporine therapy with low doses of corticosteroids on idiopathic nephrotic syndrome

Artificial Organs

Volumn 34, Issue 3, 2010, Pages 234-237

  Griveas, Ioannis ^a   Visvardis, George ^b   Papadopoulou, Dorothea ^b   Nakopolou, Lidia ^c   Karanikas, Evaggelos ^a   Gogos, Konstantina ^a   Stavianoudakis, George ^a  

^a 417 Veterans Army Administration Hospital   (Greece)

^b PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Corticosteroids; Cyclosporine; Nephrotic syndrome; Renal function

Indexed keywords

DRUG PRODUCTS; PATIENT TREATMENT;

BLOOD LEVELS; CONDITION; CORTICOSTEROID; CYCLOSPORINE; IMMUNOSUPPRESSIVE EFFECTS; LOW DOSE; NEPHROTIC SYNDROME; OPTIMISATIONS; RENAL FUNCTIONS; STANDARD DEVIATION;

BLOOD;

CHOLESTEROL; CYCLOSPORIN A; LIPID; METHYLPREDNISOLONE; PROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; KIDNEY FUNCTION; LEUKOENCEPHALOPATHY; LIPID BLOOD LEVEL; LIVER DYSFUNCTION; LOW DRUG DOSE; MALE; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77949696392     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2009.00838.x     Document Type: Article

References (11)

1. Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int 2007 72 : 1429 1447.
2. Midvedt K, Fauchald P, Bergan S, et al. C2 monitoring in maintenance renal transplant recipients: is it worthwhile? Transplantation 2003 76 : 1236 1238.
3. Bokenkamp A, Offner G, Hoyer PF, Vester U, Wonigeit K, Brodehl J. Improved absorption of cyclosporin A from a new microemulsion formulation: implications for dosage and monitoring. Pediatr Nephrol 1995 9 : 196 198.
4. Citterio F, Scata MC, Borzi MT, Pozzetto U, Castagneto M. C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients. Transpl Proc 2001 33 : 3133 3136.
5. Rosati A, Bertoni E, Zanazzi M, et al. Neoral dose monitoring with cyclosporine 2-hour post dose levels (C2) in different renal transplant patient age group. Transpl Proc 2001 33 : 3106 3107.
6. Kano M, Kyo K, Yamada Y, Ito S, Ando T, Arisaka O. Comparison between pre- and post-treatment clinical and renal biopsies in children receiving low dose cyclosporine A for 2 years for steroid-dependent nephrotic syndrome. Clin Nephrol 1999 52 : 19 24.
7. Nakahata T, Tanaka H, Tsugawa K, et al. C1-C2 point monitoring of low dose cyclosporin A given as a single daily dose in children with steroid-dependent relapsing nephrotic syndrome. Clin Nephrol 2005 64 : 258 263.
8. Innoue Y, Iijima K, Nakamura H, Yoshikawa N. Two year cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 1999 13 : 33 9.
9. Ishikura K, Ikeda M, Hattori S, et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomised multicenter trial. Kidney Int 2008 73 : 1167 1173.
10. Alexopoulos E, Papagianni M, Tsamelashvilli M, et al. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transpl 2006 21 : 3127 3132.
11. Alexopoulos E, Papagianni M, Economidou D, et al. Efficacy of cyclosporine in difficult-to-treat idiopathic membranous nephropathy. Nephrology 2002 7 : 51 5.